October 10, 2014

The Food and Drug Administration on Friday approved Gilead's Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus genotype 1 infection.

October 8, 2014

Teva Pharmaceutical Industries on Wednesday announced the initiation of a rolling new drug application submission for hydrocodone bitartrate extended-release tablets.

September 11, 2014

Medivation and Astellas Pharma on Wednesday announced that the Food and Drug Administration approved a new use of Xtandi (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer.

September 9, 2014

Sanofi Pasteur announced that the Food and Drug Administration approved the use of Menactra [meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine] as a booster vaccination against meningococcal disease in people ages 15 years through 55 years. 

September 5, 2014

Merck on Thursday announced that the Food and Drug Administration granted accelerated approval to Keytruda (pembrolizumab) for the treatment of patients with advanced melanoma.

August 26, 2014

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Co. announced that Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States.

August 19, 2014

The Food and Drug Administration has approved Mylan Institutional’s application for its dexmedetomidine hydrochloride injection, the company announced Tuesday. 

August 5, 2014

Lannett Co. on Monday announced that its abbreviated new drug application for oxycodone hydrochloride capsules, 5 mg, has been approved by the Food and Drug Administration.

July 24, 2014

Onco360, an independent oncology pharmacy and clinical support services company, announced that it has been selected to be part of the highly limited specialty pharmacy network of Zydelig tablets.

July 21, 2014

Teva Pharmaceutical Industries on Monday announced that its acquistion of Labrys has been completed. The acquisition brings to Teva LBR-101, which is currently in phase-2b clinical trials for prevention of chronic and episodic migraines.

July 9, 2014

Procter & Gamble’s Olay skin care brand has hosted the ultimate before-and-after skin care challenge to help answer the age-old debate: is beautiful skin genetic, or is there more to it?

July 3, 2014

Roche on Wednesday announced that Genentech, a member of the Roche Group, has entered into a definitive agreement to acquire Seragon Pharmaceuticals, a privately held biotechnology company based in San Diego. 

July 3, 2014

Impax Labs on Wednesday announced that it has acquired from Actavis two generic products for cash consideration. Financial terms of the agreement were not disclosed.

July 2, 2014

Upsher-Smith Laboratories on Wednesday announced the launch of testosterone gel (1%), the generic of Vogelxo (testosterone) gel 1%, for topical use. Newly approved by the Food and Drug Administration, it is the first and only available generic testosterone replacement therapy available in three configurations, the company stated.

July 1, 2014

Actavis and Forest Labs. on Monday announced that the U.S. Federal Trade Commission has voted to approve Actavis' proposed acquisition of Forest.

June 23, 2014

Lupin Pharmaceuticals last week announced the launch of ciprofloxacin oral suspension in 5 g/100 mL (250 mg/5 mL) and 10 g/100 mL (500 mg/5 mL) dosage strengths.

June 17, 2014

Lannett Co. received approval from the Food and Drug Administration for codeine sulfate tablets USP, a schedule II controlled substance, in 15 mg, 30 mg and 60 mg dosage strengths.

June 17, 2014

Novartis on Tuesday announced that it had submitted a biologic license application to the Food and Drug Administration for marketing approval for the use of Bexsero.

June 17, 2014

Teva has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to a patent for Teva’s wakefulness product, Nuvigil (armodafinil) tablets.

June 11, 2014

Strativa Pharmaceutical, a division of Par Pharmaceutical Cos., announced that the Food and Drug Administration approved Nascobal, a prescription B-12 supplement administered once a week as one spray.

June 9, 2014

Merck and Idenix Pharmaceuticals on Monday announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash.

June 9, 2014

Mylan on Monday announced the launch of carboplatin injection, 50-mg/5-ml, in multi-dose vials. The drug is the generic version of Paraplatin injection from Bristol-Myers Squibb.

June 6, 2014

Upsher-Smith Laboratories on Wednesday announced that it has received final approval from the Food and Drug Administration for its new drug application for Vogelxo (testosterone) gel for topical use CIII.

June 3, 2014

Teva Pharmaceutical and Labrys Biologics, a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, on Tuesday announced that Teva has entered into a definitive agreement to acquire Labrys in a deal for $200 million in upfront payment in cash at closing as well as up to $625 million in contingent payments upon achievement of certain pre-launch milestones.